$6.46
5.00% day before yesterday
Nasdaq, Jan 02, 10:00 pm CET
ISIN
US09075X1081
Symbol
BDSX

Biodesix Inc Stock price

$6.46
-1.37 17.50% 1M
+0.96 17.45% 6M
-0.34 5.00% YTD
-23.14 78.18% 1Y
-39.54 85.96% 3Y
-389.54 98.37% 5Y
-249.74 97.48% 10Y
-249.74 97.48% 20Y
Nasdaq, Closing price Fri, Jan 02 2026
-0.34 5.00%

Key metrics

Basic
Market capitalization
$51.4m
Enterprise Value
$81.9m
Net debt
$30.5m
Cash
$16.6m
Shares outstanding
8.0m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
0.6 | 0.6
EV/Sales
1.0 | 1.0
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
21.5%
Return on Equity
-205.7%
ROCE
-45.8%
ROIC
-
Debt/Equity
-27.4
Financials (TTM | estimate)
Revenue
$80.2m | $86.1m
EBITDA
$-26.6m | $-20.6m
EBIT
$-32.4m | $-32.1m
Net Income
$-39.5m | $-46.1m
Free Cash Flow
$-29.2m
Growth (TTM | estimate)
Revenue
22.3% | 20.8%
EBITDA
9.0% | 28.7%
EBIT
6.4% | 6.2%
Net Income
9.6% | -7.5%
Free Cash Flow
53.5%
Margin (TTM | estimate)
Gross
79.8%
EBITDA
-33.2% | -23.9%
EBIT
-40.4%
Net
-49.3% | -53.6%
Free Cash Flow
-36.5%
More
EPS
$-5.3
FCF per Share
$-3.7
Short interest
1.9%
Employees
273
Rev per Employee
$260.0k
Show more

Is Biodesix Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,082 stocks worldwide.

Biodesix Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a Biodesix Inc forecast:

9x Buy
82%
2x Hold
18%

Analyst Opinions

11 Analysts have issued a Biodesix Inc forecast:

Buy
82%
Hold
18%

Financial data from Biodesix Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
80 80
22% 22%
100%
- Direct Costs 16 16
11% 11%
20%
64 64
26% 26%
80%
- Selling and Administrative Expenses 85 85
10% 10%
105%
- Research and Development Expense 12 12
28% 28%
14%
-27 -27
9% 9%
-33%
- Depreciation and Amortization 5.73 5.73
8% 8%
7%
EBIT (Operating Income) EBIT -32 -32
6% 6%
-40%
Net Profit -40 -40
10% 10%
-49%

In millions USD.

Don't miss a Thing! We will send you all news about Biodesix Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Biodesix Inc Stock News

Neutral
GlobeNewsWire
about one month ago
Clinical utility data for Nodify Lung® tests to be presented at North American Conference on Lung Cancer (NACLC) highlighting potential for earlier diagnosis of lung cancer Development data for a new ultra-sensitive ESR1 assay for breast cancer treatment resistance monitoring to be presented at San Antonio Breast Cancer Symposium (SABCS) LOUISVILLE, Ky., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Biodes...
Neutral
Seeking Alpha
2 months ago
Biodesix, Inc. ( BDSX ) Q3 2025 Earnings Call November 3, 2025 4:30 PM EST Company Participants Scott Hutton - President, CEO & Director Robin Cowie - CFO, Secretary & Treasurer Conference Call Participants Christopher Brinzey - Westwicke Partners, LLC Margarate Boeye - William Blair & Company L.L.C., Research Division Alexander Vukasin - Canaccord Genuity Corp., Research Division Thomas Flaten...
Neutral
GlobeNewsWire
2 months ago
Q3 2025 Revenue of $21.8 million, an increase of 20% over Q3 2024; Q3 2025 gross profit margin of 81%, a 400-basis point improvement from Q3 2024; Raised FY2025 Total Revenue Guidance to $84-86 million; Conference Call and Webcast Today at 4:30 p.m. ET LOUISVILLE, Colo.
More Biodesix Inc News

Company Profile

Biodesix, Inc. provides blood-based diagnostics services for patients with lung disease. It offers GeneStrat, a genomic blood test for patients who have been diagnosed with advanced lung cancer; and VeriStrat, a serum proteomic test that provides prognostic and predictive information for patients with non-small cell lung cancer. It is a data-driven diagnostic solutions company with proprietary AI platform to discover, develop, and commercialize solutions for clinical unmet needs, with a primary focus in lung disease. The firm offers six diagnostic tests including: Nodify XL2, Nodify CDT, GeneStrat, VeriStrat, Bio-Rad SARS-CoV-2 ddPCR test and the Platelia SARS-CoV-2 test. . The company was founded in 2005 and is headquartered in Boulder, CO.

Head office United States
CEO Scott Hutton
Employees 273
Founded 2005
Website www.biodesix.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today